Newer Medications for Chronic Idiopathic Constipation
For adults with chronic idiopathic constipation who have failed over-the-counter laxatives, the three best newer medications with strong evidence are linaclotide, plecanatide, and prucalopride—all receiving strong recommendations with moderate-quality evidence from the 2023 AGA-ACG guidelines. 1
First-Tier Prescription Options (Strong Recommendations)
The 2023 AGA-ACG joint guidelines provide clear hierarchy for prescription medications when OTC agents fail:
Secretagogues (Guanylate Cyclase-C Agonists)
Linaclotide (Strong recommendation, moderate evidence) 1
- Can replace or supplement OTC agents
- Studied for 12 weeks in trials, no duration limit on drug label
- Primary side effect: Diarrhea, which may lead to discontinuation
- Mechanism: Increases intestinal fluid secretion and accelerates transit
Plecanatide (Strong recommendation, moderate evidence) 1
- Similar profile to linaclotide
- Can replace or supplement OTC agents
- Studied for 12 weeks, no duration limit on label
- Primary side effect: Diarrhea leading to potential discontinuation
- Advantage: May have better tolerability profile in some patients
Prokinetic Agent
- Prucalopride (Strong recommendation, moderate evidence) 1
- 5-HT4 receptor agonist that enhances colonic motility
- Studied for 4-24 weeks, no duration limit on label
- Can replace or supplement OTC agents
- Side effects: Headache, abdominal pain, nausea, and diarrhea
- Network meta-analysis ranked prucalopride first at 12 weeks for achieving ≥3 complete spontaneous bowel movements per week (RR 0.82,95% CI 0.78-0.86) 2
- Key advantage: Many trials recruited patients who previously failed laxatives, suggesting superior efficacy in refractory cases
Second-Tier Prescription Option (Conditional Recommendation)
- Lubiprostone (Conditional recommendation, low evidence) 1
- Chloride channel activator
- Can replace or supplement OTC agents
- Studied for 4 weeks, no duration limit on label
- Primary side effect: Nausea (dose-dependent, reduced when taken with food and water)
- Weaker recommendation reflects lower quality evidence compared to the three agents above
Clinical Decision Algorithm
Step 1: After OTC laxatives (PEG, magnesium oxide) fail, choose among the three strongly-recommended agents:
- Choose linaclotide or plecanatide if: Patient has concurrent abdominal pain or discomfort (these agents improve both motility and sensory symptoms) 3
- Choose prucalopride if: Patient has documented laxative-refractory constipation or primarily needs enhanced colonic motility without significant pain symptoms 2
Step 2: If first prescription agent causes intolerable diarrhea:
- Switch between secretagogues (linaclotide ↔ plecanatide) for potentially better tolerability
- Or switch to prucalopride (different mechanism, different side effect profile)
Step 3: If nausea is the limiting factor:
- Avoid lubiprostone
- Prucalopride may cause nausea but less commonly than lubiprostone
Important Caveats
Common Pitfall: The guidelines note that all three top-tier agents can be used as replacement OR adjunct to OTC therapies 1. Don't automatically discontinue PEG or other OTC agents—combination therapy is explicitly supported.
Duration Consideration: While trials lasted 4-24 weeks, drug labels provide no time limits for any of these agents, supporting long-term use 1.
Evidence Strength: The network meta-analysis suggests prucalopride may have the edge in truly refractory patients, as those trials specifically enrolled patients who failed laxatives 2. However, all three agents have strong recommendations with moderate evidence quality.
Emerging Options: Bile acid transporter inhibitors (elobixibat) show promise but lack widespread availability and guideline incorporation 4, 5.
Patient Satisfaction: Only one-third of CIC patients report satisfaction with symptom control, but satisfaction is significantly higher with prescription medications versus OTC-only treatment 6. This underscores the importance of escalating to these newer agents when appropriate.